This study evaluated a new blood test called the EDIM test, which measures two biomarkers, Apo10 and TKTL1, to detect cancer. These biomarkers are involved in cell growth, resistance to cell death, and tumor metabolism. The researchers tested blood samples from patients with cholangiocellular carcinoma (CCC), pancreatic cancer (PC), and colorectal cancer (CRC), comparing the results to healthy individuals and those with inflammation. The EDIM test detected cancer in 100% of the cancer patients but was negative in healthy people, showing higher sensitivity compared to traditional tumor markers. The findings suggest that the EDIM test could improve cancer detection, particularly for these types of carcinomas.
